Lysophosphatidylcholines are associated with P-tau181 levels in early stages of Alzheimer’s Disease.

We profiled circulating plasma metabolites to identify systemic biochemical changes in clinical and biomarker-assisted diagnosis of Alzheimer’s disease (AD).